CN102781441A - 大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法 - Google Patents

大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法 Download PDF

Info

Publication number
CN102781441A
CN102781441A CN2010800547916A CN201080054791A CN102781441A CN 102781441 A CN102781441 A CN 102781441A CN 2010800547916 A CN2010800547916 A CN 2010800547916A CN 201080054791 A CN201080054791 A CN 201080054791A CN 102781441 A CN102781441 A CN 102781441A
Authority
CN
China
Prior art keywords
acid
solution
salt
solvate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800547916A
Other languages
English (en)
Chinese (zh)
Inventor
H·R·霍维达
M·韦兹纳
E·富尼耶
R·加农
P·贝雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tranzyme Pharma Inc
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Publication of CN102781441A publication Critical patent/CN102781441A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2010800547916A 2009-09-30 2010-09-29 大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法 Pending CN102781441A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24736209P 2009-09-30 2009-09-30
US61/247,362 2009-09-30
PCT/US2010/050661 WO2011041369A1 (en) 2009-09-30 2010-09-29 Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same

Publications (1)

Publication Number Publication Date
CN102781441A true CN102781441A (zh) 2012-11-14

Family

ID=43826618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800547916A Pending CN102781441A (zh) 2009-09-30 2010-09-29 大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法

Country Status (14)

Country Link
US (1) US20110245159A1 (US07521420-20090421-C00691.png)
EP (1) EP2482813A4 (US07521420-20090421-C00691.png)
JP (1) JP2013506676A (US07521420-20090421-C00691.png)
KR (1) KR20120081166A (US07521420-20090421-C00691.png)
CN (1) CN102781441A (US07521420-20090421-C00691.png)
AU (1) AU2010300689A1 (US07521420-20090421-C00691.png)
BR (1) BR112012007183A2 (US07521420-20090421-C00691.png)
CA (1) CA2775925A1 (US07521420-20090421-C00691.png)
EA (1) EA201270497A1 (US07521420-20090421-C00691.png)
IL (1) IL218938A0 (US07521420-20090421-C00691.png)
IN (1) IN2012DN03297A (US07521420-20090421-C00691.png)
MX (1) MX2012003912A (US07521420-20090421-C00691.png)
WO (1) WO2011041369A1 (US07521420-20090421-C00691.png)
ZA (1) ZA201202307B (US07521420-20090421-C00691.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087530A (zh) * 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
WO2004111077A1 (en) * 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG11201703884PA (en) 2014-11-12 2017-06-29 Lyric Pharmaceuticals Inc Treatment of enteral feeding intolerance
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
KR20070009574A (ko) * 2004-02-17 2007-01-18 토마스 이. 존슨 매크로사이클릭 화합물의 형성을 위한 방법, 조성물 및장치
CN102816194A (zh) * 2004-02-27 2012-12-12 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087530A (zh) * 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统

Also Published As

Publication number Publication date
IN2012DN03297A (US07521420-20090421-C00691.png) 2015-10-23
KR20120081166A (ko) 2012-07-18
EP2482813A4 (en) 2013-02-27
US20110245159A1 (en) 2011-10-06
MX2012003912A (es) 2012-08-17
AU2010300689A1 (en) 2012-04-19
ZA201202307B (en) 2012-12-27
CA2775925A1 (en) 2011-04-07
BR112012007183A2 (pt) 2017-06-20
JP2013506676A (ja) 2013-02-28
IL218938A0 (en) 2012-07-31
EP2482813A1 (en) 2012-08-08
EA201270497A1 (ru) 2012-10-30
WO2011041369A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CN102781441A (zh) 大环生长素释放肽受体激动剂的盐、溶剂合物和药物组合物及其使用方法
KR100967070B1 (ko) 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
TWI699367B (zh) 用於製備丁基原啡因之方法
US9150567B2 (en) Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN101784273A (zh) (2s,3r)-n-(2-((3-吡啶基)甲基)-1-氮杂双环[2.2.2]辛-3-基)苯并呋喃-2-甲酰胺、其新的盐形式和用法
RU2723095C1 (ru) Соединение для применения в лечении нейрогенной ортостатической гипотензии
JP5981940B2 (ja) アジルサルタン有機アミン塩、その製造方法及び使用
KR20130138770A (ko) 광학적으로 활성 산을 갖는 로르카세린의 염
SK284941B6 (sk) Použitie (+)-norcisapridu na výrobu liečiva na liečenie porúch zažívacieho traktu
US9663439B2 (en) Aildenafil citrate crystal form O, preparation method and use thereof
US20210323908A1 (en) Process for producing tca cycle intermediate conjugates
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
US20110200687A1 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
JP2013507345A (ja) インビボイメージング剤としてのフルマゼニルの［１８ｆ］標識類似体
WO2009075504A2 (en) Crystalline form of bepotastine p-toluenesulfonate, method for preparing same and pharmaceutical composition containing same
TWI326684B (US07521420-20090421-C00691.png)
US8198268B2 (en) Tianeptine sulfate salt forms and methods of making and using the same
JP2004529982A (ja) 逆流症に有効な新規な化合物
EP1888577B1 (en) Ocaperidone salts and pharmaceutical compositions containing the same
CN108250219B (zh) 一种治疗甲状腺炎的药物及其制备方法
JP2005511611A (ja) インテグリン受容体拮抗薬のアミン塩
WO2022247885A9 (zh) 三并杂环类化合物的结晶和盐及其应用
CN102666528A (zh) 晶体cdc7 抑制剂盐
WO2021207577A1 (en) Process for producing tca cycle intermediate conjugates and polymorphs of a tca cycle intermediate conjugate
EP2527319A1 (en) Crystalline forms of pregabalin and co-formers in the treatment of pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121114